THERAVANCE (NASDAQ:THRX)
14.04
0.13 (0.92%)
| THERAVANCE (NASDAQ:THRX) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $14.17 | 52 Week High | $18.56 | ||
| Open | $13.99 | 52 Week Low | $4.32 | ||
| Day High | $14.35 | P/E | N/A | ||
| Day Low | $13.57 | EPS | $-1.27 | ||
| Volume | 217,175 | ||||
| More THRX Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| GSK | 2 | AMED | 1 |
| CHE | 1 | ENWV | 1 |
| KWR | 1 | POOL | 1 |
| UA | 1 | BBOX | 1 |
| CSGS | 1 | GKSR | 1 |
| MRCY | 1 | RYN | 1 |
Entities who have mentioned THRX
- UBS | View Related Stories »
- Robert W Baird | View Related Stories »
- Credit Suisse | View Related Stories »
- Soleil Securities | View Related Stories »
- Warren Buffett | View Related Stories »
- JPMorgan | View Related Stories »
- Citi | View Related Stories »
- Banc of America | View Related Stories »
- Susquehanna International Group of Companies | View Related Stories »
- ThinkEquity | View Related Stories »
- Consumer Confidence Index | View Related Stories »
- Trading Radar | View Related Stories »
View All Major News StreetInsider.com Major News for THRX
- Theravance (THRX) Posts Q3 Loss of $0.35; Revs Light
- Theravance (THRX) Reports In-Line Q2 Loss of $0.35
- Theravance (THRX) Reports Better-Than-Expected Q1 Loss of $0.31
View All ReportsStreetInsider.com Reports on THRX
- Theravance (THRX) Posts Q3 Loss of $0.35; Revs Light
- Trading Radar for 10/27: Visa (V), Baidu.com (BIDU), WYNN Resorts (WYNN), RF Micro (RFMD), BP (BP) Report
- Astellas and Theravance (THRX) Announce Approval of VIBATIV (telavancin) in Canada
- FTN Equity Initiates Coverage on Theravance (THRX) with a Neutral
- Theravance (THRX) Announces FDA Approva For VIBATIV
View All Press ReleasesCompany Press Releases on THRX
- Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
- Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
- Theravance to Present at the 18th Annual Credit Suisse Health Care Conference
- Theravance Announces New Employment Inducement Award
- Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe
StreetInsider Reports on THRX by Category
View All BlogsBlogs on THRX
- Baupost Group's Q3 Portfolio: Two Changes of Note
- Baupost Group's Massive Position in CapitalSource
- FDA Calendar: 2H09 Binary Event Trades
- 15 Overvalued Small Caps from Russell 2000
- 2009 Looking Good for Theravance
View All FilingsSEC Filings on THRX
- Form 10-Q THERAVANCE INC For: Sep 30
- Form 8-K THERAVANCE INC For: Oct 27
- Form 8-K THERAVANCE INC For: Oct 23
Comments on recent THRX articles
Comments on THRX
No comments are currently available.
on Oct 28, 2009
at 05:29 PM ANDREW OLIVER SATCHELL GOOD
Article: Trading Radar for 10/27: Visa (V), Baidu.com (BIDU), WYNN Resorts (WYNN), RF Micro (RFMD), BP (BP) Report